Article Text

Download PDFPDF
P117 Centralization and implementation of national guidelines of ovarian cancer improves survival – a population-based nationwide SweGCG study
  1. P Dahm Kähler1,2,
  2. C Borgfeldt3,
  3. A Flöter Rådestad4,
  4. E Hjerpe4,
  5. J Marcickiewicz2,
  6. M Bjurberg5,
  7. B Tholander6,
  8. K Hellman7,
  9. P Kjølhede8,
  10. T Högberg9,
  11. P Rosenberg10,
  12. E Åvall-Lundqvist11 and
  13. K Stålberg6
  1. 1Dept Obst and Gynecology, Sahlgrenska University Hospital
  2. 2Sahlgrenska Academy at University of Gothenburg, Institute of Clinical Sciences, Göteborg
  3. 3Dept Obst and Gynecology, Skane University Hospital, Lund University, Lund
  4. 4Dept of Women’s and Children’s Health, Karolinska University Hospital and Karolinska Institutet, Stockholm
  5. 5Dept of Clinical Sciences, Skane University Hospital, Lund University, Lund
  6. 6Dept of Women’s and Children’s Health, Uppsala University, Uppsala
  7. 7Dept of Women’s and Children’s Health, Karolinska University Hospital and Karolinska Institute, Stockholm
  8. 8Dept Obst and Gynecology, Dept of Clinical and Experimental Medicine, Linköping University, Linköping
  9. 9Dept of Cancer Epidemiology, Lund University, Lund
  10. 10Dept of Oncology, University Hospital Linköping
  11. 11Dept of Oncology and of Clinical and Experimental Medicine, Linköping University, Linköping, Sweden


Introduction/Background Ovarian cancer is the leading cause of death due to gynecological cancers, the majority are diagnosed in advanced stages. The first Swedish national guidelines for ovarian cancer, implemented in 2012, recommended centralization to tertiary centres and primary debulking surgery (PDS) to no macroscopic residual disease (R0) as gold standard. Neoadjuvant chemotherapy (NACT) followed by interval debulking surgery (IDS) was recommended according to predefined criteria. The aim of this study was to evaluate overall survival (OS) before and after the implementation of the national guidelines.

Methodology Women diagnosed with epithelial ovarian/fallopian tube cancers FIGO stages III-IV and registered in the population-based nationwide Swedish Quality Registry for Gynecologic Cancer (SQRGC) between 2008–2016 were eligible excluding those diagnosed in 2012. Comparisons of OS before and after the implementation, 2008–2011vs 2013–2016, were performed in the cohorts of PDS, NACT+IDS and the total cohort. Overall survival (OS) was assessed by the Kaplan-Meier method and log rank test. The validity of SQRGC has previously been reported.1

Results In total, 3196 women were included in the study (n=1577 before and n=1619 after the implemented guidelines). PDS was performed in 937 (59%) women before and in 1038 (64%) women after the guidelines were introduced. During the same time periods the proportion of complete cytoreduction to R0 increased from 33% to 58%. In the PDS cohort, 5-year OS rate increased significantly from 29% (95% CI: 26–32%) to 40% (95% CI: 36–44%). In the NACT+IDS cohort, no significant difference in OS was observed. In the total cohort, 5-year OS increased significantly from 25% (95% CI: 23–28%) before to 34% (95% CI: 31–37%) after the introduction of national guidelines.

Conclusion Centralization and implementation of the first Swedish national guidelines significantly improved 5-year overall survival in the total cohort of stages III-IV epithelial ovarian cancer.

Disclosure Nothing to disclose.

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.